At the present time there are novel hypolipidemics registered globally 
(alirocumab was the first drug of this group in the world registered by an 
American drug agency FDA) and in Europe, which in many ways differ from the 
medicines administered until now. They are bringing another advancement in the 
treatment of disorders of lipid metabolism and in preventive cardiology. 
Alirocumab is a fully human monoclonal antibody to PCSK-9 enzyme (proprotein 
convertase subtilisin kexin-9). PCSK-9 enzyme plays an important role in the 
metabolism of LDL-cholesterol through affecting the breakdown and eventually the 
amount and activity of LDL-receptors. From the clinical point of view it is 
essential that drugs from this group are administered parenterally, as a 
subcutaneous injection. In the case of Praluent® the interval between 
administration is two weeks. The dose is then 75 or 150 mg in a 1 ml injection. 
From the clinical point of view it is particularly important that alirocumab 
decreases LDL-C concentrations by 50-60%, it decreases Lp/a/ levels by 25-30%, 
and it also positively influences other components of lipid metabolism and, 
above all, is very likely to have a potential to decrease a cardiovascular risk. 
Although the resuIts of morbidity and mortality studies are expected in the 
coming years, initial analyses strongly indicate a clinically significant 
reduction of CV events. Alirocumab, Praluent can be administered as monotherapy 
(mainly to statin-intolerant patients), however it will be primarily 
administered in combination with the other hypolipidemic drugs (in particular 
statins) where the effort to reach target values has not succeeded.